TY - JOUR
T1 - Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock
AU - Ognibene, F. P.
AU - Rosenberg, S. A.
AU - Lotze, M.
AU - Skibber, J.
AU - Parker, M. M.
AU - Shelhamer, J. H.
AU - Parrillo, J. E.
PY - 1988
Y1 - 1988
N2 - Interleukin-2, a lymphocyte product, has well demonstrated antitumor activity in humans. Early clinical studies showed hemodynamic alterations in patients receiving the drug as antitumor immunotherapy. We serially assessed interleukin-2-associated hemodynamic parameters and left ventricular ejection fractions in five patients with neoplastic diseases unresponsive to conventional therapies. By day 4 of therapy, compared with baseline (preinterleukin-2), all patients developed tachycardia (p < 0.01), decreased mean arterial blood pressure (p < 0.05), increased cardiac index (p < 0.05), and decreased systemic vascular resistance (p < 0.01). In addition, left ventricular ejection fraction fell from 58.0 ± 4.7 to 36.4 ± 4.0 percent (0.05 < p < 0.10), which was associated with a trend toward left ventricular dilatation manifested by an increase in left ventricular end-diastolic volume index. Transient renal dysfunction was noted in all five patients, and one developed transient respiratory failure; both types of organ dysfunction recovered to baseline values after cessation of immunotherapy. Thus, interleukin-2 induces multiple reversible cardiovascular abnormalities that are similar to the hemodynamic manifestations of human septic shock.
AB - Interleukin-2, a lymphocyte product, has well demonstrated antitumor activity in humans. Early clinical studies showed hemodynamic alterations in patients receiving the drug as antitumor immunotherapy. We serially assessed interleukin-2-associated hemodynamic parameters and left ventricular ejection fractions in five patients with neoplastic diseases unresponsive to conventional therapies. By day 4 of therapy, compared with baseline (preinterleukin-2), all patients developed tachycardia (p < 0.01), decreased mean arterial blood pressure (p < 0.05), increased cardiac index (p < 0.05), and decreased systemic vascular resistance (p < 0.01). In addition, left ventricular ejection fraction fell from 58.0 ± 4.7 to 36.4 ± 4.0 percent (0.05 < p < 0.10), which was associated with a trend toward left ventricular dilatation manifested by an increase in left ventricular end-diastolic volume index. Transient renal dysfunction was noted in all five patients, and one developed transient respiratory failure; both types of organ dysfunction recovered to baseline values after cessation of immunotherapy. Thus, interleukin-2 induces multiple reversible cardiovascular abnormalities that are similar to the hemodynamic manifestations of human septic shock.
UR - http://www.scopus.com/inward/record.url?scp=0023750345&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023750345&partnerID=8YFLogxK
U2 - 10.1378/chest.94.4.750
DO - 10.1378/chest.94.4.750
M3 - Article
C2 - 3262487
AN - SCOPUS:0023750345
SN - 0012-3692
VL - 94
SP - 750
EP - 754
JO - CHEST
JF - CHEST
IS - 4
ER -